NCT05537259

Brief Summary

The overall goal of the BUMPP study is to improve our understanding of a range of moods, feelings, and thoughts that women can experience during pregnancy and soon after they give birth. This study will examine how these moods, feelings, and thoughts are related to changes in hormonal and immune health that women experience during and after pregnancy, and to mother-baby relationships and infant development in the early postpartum months.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
168

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2022

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 27, 2022

Completed
9 days until next milestone

First Submitted

Initial submission to the registry

July 6, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

September 13, 2022

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 7, 2023

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

February 20, 2024

Completed
Last Updated

January 13, 2025

Status Verified

January 1, 2025

Enrollment Period

1.4 years

First QC Date

July 6, 2022

Last Update Submit

January 9, 2025

Conditions

Keywords

PregnancyPostpartumMental Health

Outcome Measures

Primary Outcomes (6)

  • Self-report questionnaire measure of depressive symptoms (Edinburgh Postnatal Depression Scale)

    Assessed at each of 4 sessions

    35 weeks of pregnancy through 2 months postpartum

  • Self-report questionnaire measure of anxiety symptoms (Generalized Anxiety Disorder-7)

    Assessed at each of 4 sessions

    35 weeks of pregnancy through 2 months postpartum

  • Self-report questionnaire measure of manic symptoms (Highs Scale)

    Assessed at each of 4 sessions

    35 weeks of pregnancy through 2 months postpartum

  • Self-report questionnaire measure of symptoms of psychosis (subscales of Symptom Checklist-90)

    Assessed at each of 4 sessions

    35 weeks of pregnancy through 2 months postpartum

  • Mother-infant behavior during 5 min play episode coded using Global Rating Scales

    Assessed at in-person laboratory session (session 4)

    2 months postpartum

  • Bayley Scales of Infant Development, 4th edition, to assess infant cognitive development

    Assessed at in-person laboratory session (session 4)

    2 months postpartum

Secondary Outcomes (2)

  • Monthly cortisol levels determined from hair sample

    35 weeks of pregnancy through 2 months postpartum

  • Cytokine levels determined from finger prick blood spot

    35 weeks of pregnancy through 2 months postpartum

Study Arms (1)

Observation Group

Researchers will collect data on maternal mental health symptoms, as well as health and psychosocial factors, via short interviews (sessions 1 and 4) and via self-report questionnaires completed through REDCap at each session. Participating women will also provide one small hair sample (session 4) for measurement of the stress hormone cortisol and several finger stick blood spot samples (sessions 1,2, and 4) for measurement of immune markers.

Other: Observation Group

Interventions

No intervention; this is an observational study.

Observation Group

Eligibility Criteria

Age18 Years+
Sexfemale
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Pregnant women and their infants

You may qualify if:

  • years or older
  • weeks pregnant or less
  • carrying only one baby (not twins or triplets)
  • first time giving birth
  • can speak/read/write in English

You may not qualify if:

  • major medical health condition like a heart, kidney, or liver disease or HIV
  • currently taking corticosteroids, progesterone, or immunosuppressive medications that might impact the samples we are taking in this research study
  • have regularly used alcohol, tobacco, or recreational drugs (such as marijuana or prescription drugs for non-medical reasons) during pregnancy (regularly means more than a few times total, such as on a monthly, weekly, or daily basis)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Minnesota

Minneapolis, Minnesota, 55455, United States

Location

MeSH Terms

Conditions

Psychological Well-Being

Condition Hierarchy (Ancestors)

Personal SatisfactionBehavior

Study Officials

  • Megan Gunnar, PhD

    University of Minnesota

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 6, 2022

First Posted

September 13, 2022

Study Start

June 27, 2022

Primary Completion

November 7, 2023

Study Completion

February 20, 2024

Last Updated

January 13, 2025

Record last verified: 2025-01

Locations